We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Pulsed Field Ablation Offers Breakthrough in Treatment of Atrial Fibrillation

By HospiMedica International staff writers
Posted on 27 May 2022

Catheter ablation has long been recognized as an effective treatment for a wide variety of cardiac arrhythmias, but the therapy runs a risk of damage to surrounding tissues. More...

Now, pulsed field ablation (PFA) is emerging as a novel, non-thermal energy source that may offer a safer alternative to conventional catheter ablation technologies. PFA delivers ultrashort, high-voltage pulses to create lesions on targeted tissue. This mechanism is also known as electroporation because it causes temporary pore-like openings in cell walls, leading to death by apoptosis. The frequency of the pulses can be adjusted to target specific proteins within cell membrane, leaving other types of tissue unharmed.

Previously used in oncology to destroy specific types of tumors or to increase tumor permeability to chemotherapy drugs, PFA has recently been adapted for catheter ablation by a number of manufacturers. European regulators approved the first such device in January 2021, but the technology remains investigational in the U.S. NYU Langone (New York, NY, USA) is currently conducting clinical trials of three different PFA cardiac ablation devices in patients with atrial fibrillation.

Across the three trials testing devices developed by Medtronic, Farapulse, and Biosense Webster, primary outcomes include primary adverse events such as atrial-esophageal fistula and cardiac tamponade/perforation within seven days, and freedom from documented atrial arrhythmia, atrial tachycardia, or atrial flutter for up to one year. Secondary outcomes include the number of patients who achieve acute procedural success, defined as confirmation of entrance block in targeted atrial pulmonary veins after adenosine/isoproterenol challenge, and change in quality of life after ablation.

PFA could replace radiofrequency and cryoablation as the premier energy source for cardiac ablation. Eventually, it could be adapted beyond atrial fibrillation to other arrhythmias, including those involving the ventricles. However, numerous questions about the new technology remain, including how durable are the lesions that PFA produces, the safety compared with conventional counterparts, and which of the available catheters is optimal for a given application, such as paroxysmal versus persistent atrial fibrillation.

“With traditional energy sources, we spend much of our time trying to avoid collateral damage to the nerves, blood vessels, lungs, or esophagus,” said Larry A. Chinitz, MD, director of the Heart Rhythm Center. “PFA offers the hope for an energy source that is instantaneous, efficacious, and specific to the heart.”

Related Links:
NYU Langone 


Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Leg Wraps
Leg Wraps
New
Ultra-Low Temperature Freezer
iUF118-GX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: the deep tissue in vivo sound printing (DISP) platform, which combines ultrasound with low-temperature–sensitive liposomes loaded with crosslinking agents (Photo courtesy of Elham Davoodi and Wei Gao/Caltech)

New Ultrasound-Guided 3D Printing Technique to Help Fabricate Medical Implants

3D bioprinting technologies hold considerable promise for advancing modern medicine by enabling the production of customized implants, intricate medical devices, and engineered tissues designed to meet... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.